Literature DB >> 19387436

Biomarker discovery: identification of a growth factor gene signature.

A Loboda1, M Nebozhyn, C Cheng, R Vessey, P Huang, H Dai, J W Watters.   

Abstract

Gene expression signatures can be developed as comprehensive pathway readouts and used as pharmacodynamic or patient-stratification biomarkers. While a consensus on the best practices for selecting gene expression signatures from microarray data is evolving, we have developed basic guidelines to ensure consistency and quality. Here we illustrate these guidelines through the identification of a growth factor gene expression signature that is responsive to phosphatidylinositol 3-kinase (PI3K) pathway perturbations in vitro and related to phosphatase and tensin homolog (PTEN) deregulation in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387436     DOI: 10.1038/clpt.2009.48

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  Inhibition of Ciliogenesis Promotes Hedgehog Signaling, Tumorigenesis, and Metastasis in Breast Cancer.

Authors:  Nadia B Hassounah; Martha Nunez; Colleen Fordyce; Denise Roe; Ray Nagle; Thomas Bunch; Kimberly M McDermott
Journal:  Mol Cancer Res       Date:  2017-06-13       Impact factor: 5.852

2.  High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.

Authors:  Beate C Litzenburger; Chad J Creighton; Anna Tsimelzon; Bonita T Chan; Susan G Hilsenbeck; Tao Wang; Joan M Carboni; Marco M Gottardis; Fei Huang; Jenny C Chang; Michael T Lewis; Mothaffar F Rimawi; Adrian V Lee
Journal:  Clin Cancer Res       Date:  2010-12-22       Impact factor: 12.531

3.  A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

Authors:  Emily M Fox; Todd W Miller; Justin M Balko; Maria G Kuba; Violeta Sánchez; R Adam Smith; Shuying Liu; Ana María González-Angulo; Gordon B Mills; Fei Ye; Yu Shyr; H Charles Manning; Elizabeth Buck; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-09-09       Impact factor: 12.701

4.  Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Authors:  Jeeyun Lee; Yong Sang Hong; Jung Yong Hong; Se Won Han; Tae Won Kim; Hye Jin Kang; Tae You Kim; Kyu-Pyo Kim; Suk Hyung Kim; In-Gu Do; Kyoung-Mee Kim; Insuk Sohn; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Yong Beom Cho; Woo Yong Lee; Seong Hyeon Yun; Hee Cheol Kim; Young Suk Park; Won Ki Kang
Journal:  Invest New Drugs       Date:  2014-01-28       Impact factor: 3.850

5.  A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Authors:  Andrey Loboda; Michael Nebozhyn; Rich Klinghoffer; Jason Frazier; Michael Chastain; William Arthur; Brian Roberts; Theresa Zhang; Melissa Chenard; Brian Haines; Jannik Andersen; Kumiko Nagashima; Cloud Paweletz; Bethany Lynch; Igor Feldman; Hongyue Dai; Pearl Huang; James Watters
Journal:  BMC Med Genomics       Date:  2010-06-30       Impact factor: 3.063

6.  Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.

Authors:  A M Gonzalez-Angulo; G R Blumenschein
Journal:  Cancer Treat Rev       Date:  2012-12-06       Impact factor: 12.111

7.  Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks.

Authors:  Florian Martin; Ty M Thomson; Alain Sewer; David A Drubin; Carole Mathis; Dirk Weisensee; Dexter Pratt; Julia Hoeng; Manuel C Peitsch
Journal:  BMC Syst Biol       Date:  2012-05-31

8.  PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.

Authors:  Christophe Rosty; Joanne P Young; Michael D Walsh; Mark Clendenning; Kristy Sanderson; Rhiannon J Walters; Susan Parry; Mark A Jenkins; Aung Ko Win; Melissa C Southey; John L Hopper; Graham G Giles; Elizabeth J Williamson; Dallas R English; Daniel D Buchanan
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.